JP2013009960A - Rapidly dissolving method for microneedle - Google Patents
Rapidly dissolving method for microneedle Download PDFInfo
- Publication number
- JP2013009960A JP2013009960A JP2012149875A JP2012149875A JP2013009960A JP 2013009960 A JP2013009960 A JP 2013009960A JP 2012149875 A JP2012149875 A JP 2012149875A JP 2012149875 A JP2012149875 A JP 2012149875A JP 2013009960 A JP2013009960 A JP 2013009960A
- Authority
- JP
- Japan
- Prior art keywords
- microneedle
- microneedle array
- moisture
- skin
- back surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 239000002390 adhesive tape Substances 0.000 claims abstract description 8
- 239000006210 lotion Substances 0.000 claims abstract description 6
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 4
- 238000004090 dissolution Methods 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 5
- 230000003796 beauty Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000003491 array Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract 1
- 239000011800 void material Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 25
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000758 substrate Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
本発明は皮膚表層及び／又は皮膚角質層に修飾効果及び／又は機能効果を与えるためのマイクロニードルを皮膚内に刺入後迅速に溶解させる方法に関する。The present invention relates to a method for rapidly dissolving a microneedle for providing a modifying effect and / or a functional effect to the skin surface layer and / or the skin stratum corneum after being inserted into the skin.
薬物を人の体内に投与する手法として、経口的投与法と経皮的投与法がある。注射は代表的な経皮的投与法である。しかし、注射は医師や看護師の手を煩わせねばならず、苦痛を伴い、更にエイズやＢ型肝炎などの感染もあり得る、多くの人にとって歓迎すべからざる手法である。これに対し、最近マイクロニードルアレイを利用した、苦痛を伴わない経皮的投与法が注目されてきた（特許文献１、非特許文献１）。As a method for administering a drug into a human body, there are an oral administration method and a transdermal administration method. Injection is a typical transdermal method of administration. However, injection is an indispensable technique for many people who must bother doctors and nurses, and can be painful and can also cause infections such as AIDS and hepatitis B. On the other hand, a transdermal administration method using a microneedle array without causing pain has recently attracted attention (Patent Document 1, Non-Patent Document 1).
皮膚角質層は薬物透過のバリアとして働き、単に皮膚表面に薬物を塗布するだけでは薬物は十分に透過しない。これに対し微小な針、すなわちマイクロニードルを用いて角質層を穿孔することにより、塗布法より薬物透過効率を格段に向上させることができる。このマイクロニードルを基板上に多数集積したものがマイクロニードルアレイである。また、マイクロニードルアレイに、マイクロニードルアレイを皮膚に付着させるための粘着テープや使用まで無菌状態を維持するためのカバーシートなどを付加して使用しやすい製品としたものをマイクロニードルパッチという。
ここにテープとは、フィルム、もしくは布又は紙に粘着剤を塗布したものをいう。The skin stratum corneum acts as a barrier for drug permeation, and simply applying a drug to the skin surface does not sufficiently penetrate the drug. On the other hand, by perforating the stratum corneum using a fine needle, that is, a microneedle, the drug permeation efficiency can be remarkably improved as compared with the coating method. A microneedle array is a large number of microneedles integrated on a substrate. A product that is easy to use by adding an adhesive tape for attaching the microneedle array to the skin or a cover sheet for maintaining sterility until use is called a microneedle patch.
Here, the tape means a film or cloth or paper coated with an adhesive.
糖質など体内で溶解し代謝により消失する物質を素材としてマイクロニードルを作成すれば、仮にニードルが折れ皮膚内に残存したとしても事故とはならない。そればかりか、糖質中に薬物を含ませておくならば、刺入されたマイクロニードルが体内で溶解されることにより、容易に薬物を皮内や皮下に投与することができる（特許文献２）。
特に、ヒアルロン酸やコラーゲンなどの生体溶解性高分子物質からなるマイクロニードルを皮膚に刺入すると、皮膚内水分がマイクロニードルに拡散し、皮膚に差し込まれたニードル部が膨潤しその後溶解する。この結果ヒアルロン酸やコラーゲンが皮膚内に拡散して抗しわ作用を発現し、あるいはニードル部に前もって溶解させている薬物や有価物質が皮膚内に拡散する（特許文献３、４）。If a microneedle is made of a material that dissolves in the body and disappears by metabolism, such as carbohydrates, even if the needle breaks and remains in the skin, no accident will occur. In addition, if the drug is contained in the sugar, the inserted microneedle is dissolved in the body, so that the drug can be easily administered intracutaneously or subcutaneously (Patent Document 2). ).
In particular, when a microneedle made of a biosoluble polymer substance such as hyaluronic acid or collagen is inserted into the skin, moisture in the skin diffuses into the microneedle, and the needle portion inserted into the skin swells and then dissolves. As a result, hyaluronic acid and collagen diffuse into the skin and develop an anti-wrinkle action, or drugs and valuable substances that have been dissolved in advance in the needle portion diffuse into the skin (Patent Documents 3 and 4).
マイクロニードルが皮膚内で膨潤し溶解するには、その間マイクロニードルアレイを皮膚表面に安定的に保持する必要がある。通常、マイクロニードルアレイよりも大面積の粘着性保護テープをマイクロニードルアレイにかぶせて皮膚表面に押しつけ、その保護テープの粘着性により密着保持している。In order for the microneedles to swell and dissolve in the skin, it is necessary to stably hold the microneedle array on the skin surface. Usually, an adhesive protective tape having a larger area than the microneedle array is placed on the microneedle array and pressed against the surface of the skin, and is closely held by the adhesiveness of the protective tape.
しかしながらこの粘着性保護テープはマイクロニードルの皮膚内での溶解性に大きな影響を与える。水蒸気透過性の高い粘着保護テープを用いると、マイクロニードルを通して皮膚からマイクロニードルアレイに入った水分が蒸散し、マイクロニードルが十分に膨潤しなくなり、薬物を皮膚内に放散する速度が落ちる。また、水蒸気透過性が低い粘着保護テープを用いると、皮膚からの水分蒸散をテープが抑えるため皮膚刺激が強くなる欠点を有する。However, this adhesive protective tape greatly affects the solubility of microneedles in the skin. When an adhesive protective tape having a high water vapor permeability is used, moisture entering the microneedle array from the skin through the microneedles evaporates, the microneedles do not swell sufficiently, and the rate at which the drug is diffused into the skin decreases. In addition, when an adhesive protective tape having low water vapor permeability is used, there is a disadvantage that the skin irritation becomes strong because the tape suppresses water evaporation from the skin.
いずれにせよ、マイクロニードルを膨潤させるための水分補給が皮膚からのみでは、マイクロニードルの膨潤及び溶解に多大の時間を有する。従来マイクロニードルアレイを皮膚表面上に１〜３時間保持しておく必要があった。このためマイクロニードルアレイを顔面に装着する際には就寝前に装着することが多く、皮膚科医院や美容室で装着することは困難であった。In any case, if the hydration for swelling the microneedles is only from the skin, it takes a lot of time to swell and dissolve the microneedles. Conventionally, it was necessary to hold the microneedle array on the skin surface for 1 to 3 hours. For this reason, when the microneedle array is mounted on the face, it is often mounted before going to bed, and it is difficult to mount the microneedle array in a dermatology clinic or a beauty salon.
マイクロニードルを利用する化粧品は、コスメディ製薬により世界で初めて商業的に製造され、２００８年１０月より発売された（非特許文献１）。このマイクロニードルは膨潤と溶解にかなりの時間を要したため、需用者からはマイクロニードルの溶解速度を早め、迅速に適用できるよう改善することが強く要望されていた。Cosmetics using microneedles were first commercially produced by Cosmedy Pharmaceutical and were launched in October 2008 (Non-patent Document 1). Since the microneedles required a considerable amount of time for swelling and dissolution, there was a strong demand from users to improve the microneedle dissolution rate so that it can be applied quickly.
本発明が解決しようとする課題は、速やかに膨潤し、速やかに溶解し、速やかに吸収させうるマイクロニードルアレイを提供して、従来技術の前記の問題点を解決することである。マイクロニードルアレイの膨潤と溶解に時間がかかるのは、マイクロニードルアレイへの水分補給が不十分であったためである。必要な水分を供給しやすいマイクロニードルパッチの設計を検討した。The problem to be solved by the present invention is to solve the above-mentioned problems of the prior art by providing a microneedle array that can swell quickly, dissolve quickly, and absorb quickly. It takes time to swell and dissolve the microneedle array because the water supply to the microneedle array was insufficient. We examined the design of a microneedle patch that can easily supply the necessary moisture.
上記課題を解決するためになされた本発明に係わるマイクロニードルアレイの迅速溶解法は、マイクロニードルパッチの背面の粘着テープに空孔を設け、マイクロニードルアレイの背面より水分を供給することを特徴とする。ここにマイクロニードルアレイの背面とは、マイクロニードルが備えられた面の反対側の面をいう。The rapid dissolution method of the microneedle array according to the present invention made to solve the above-mentioned problem is characterized in that a hole is provided in the adhesive tape on the back surface of the microneedle patch, and moisture is supplied from the back surface of the microneedle array. To do. Here, the back surface of the microneedle array refers to the surface opposite to the surface on which the microneedles are provided.
マイクロニードルアレイの背面の、粘着テープの空孔は、マイクロニードルアレイの背面の面積の２０−９５％とすることができる。２０％以下では均一な水分供給が困難となり、９５％以上ではマイクロニードルアレイの保持が困難となる。
特に、６０−９０％とすることが好適である。The pores of the adhesive tape on the back of the microneedle array can be 20-95% of the area of the back of the microneedle array. If it is 20% or less, uniform water supply is difficult, and if it is 95% or more, it is difficult to hold the microneedle array.
In particular, 60 to 90% is preferable.
マイクロニードルアレイの背面より供給する水分は無菌であることが望ましく、マイクロニードルアレイの背面に供給する水分としては、化粧水を好適に用いることができる。具体的には、化粧水もしくは美容液含有ガーゼ、不織布、若しくはテープを４角形、円形、楕円形、勾玉形、フェイス状マスクとしてマイクロニードルアレイ背面に密着させるか、又は水性ゲルのパックを密着させることにより、目的を達することができる。It is desirable that the water supplied from the back surface of the microneedle array is sterile, and a lotion can be suitably used as the water supplied to the back surface of the microneedle array. Specifically, a lotion or cosmetic liquid-containing gauze, non-woven fabric, or tape is closely attached to the back of the microneedle array as a quadrangular, circular, elliptical, slanted, or face mask, or an aqueous gel pack is closely attached. The purpose can be achieved.
マイクロニードルアレイ背面に貼付する化粧水もしくは美容液含有ガーゼ、不織布、あるいは水性ゲルパックは、マイクロニードルアレイの背面空孔部全体を覆う大きさか、あるいはそれより各方向に大きいことが望ましい。
マイクロニードルを構成するヒアルロン酸やコラーゲンは、吸湿すると膨潤し、皮膚内で膨潤するとその内部へ溶けていく。従来のマイクロニードルアレイ背面全体に粘着シートを貼付する方式では、水分は皮膚内からニードルに供給されるのみで、そのためニードルは次第に膨潤し溶解してはいくものの、多くの時間を要していた。
これに対しマイクロニードル背面の粘着テープに空孔を設けて大量の水分を供給すると、マイクロニードルの基板からニードルまで全体が速やかに膨潤し、皮膚内でのニードルの溶解速度が高まる。そのため従来溶解に１〜３時間要していたマイクロニードルが、１０〜３０分で溶解することとなる。
本発明のマイクロニードルは、ヒアルロン酸やコラーゲンのような生体内溶解物質を素材とし、マイクロニードルの長さは３０−１０００μｍとした。マイクロニードルアレイの基板の大きさは特に限定する必要はないが、典型的には基板面積０．５〜４０ｃｍ２、基板厚み１０〜２０００μとした。またその形状は円形、楕円形、勾玉形、フェイス状マスクなど種々の形状が可能である。It is desirable that the lotion or cosmetic liquid-containing gauze, non-woven fabric, or aqueous gel pack to be attached to the back surface of the microneedle array should be large enough to cover the entire back pores of the microneedle array, or larger in each direction.
The hyaluronic acid and collagen constituting the microneedle swell when it absorbs moisture, and dissolves into the inside when it swells in the skin. In the conventional method of attaching an adhesive sheet to the entire back surface of the microneedle array, moisture is only supplied from the inside of the skin to the needle, so that the needle gradually swells and dissolves, but takes a lot of time. .
In contrast, when a large amount of moisture is supplied by providing pores in the adhesive tape on the back of the microneedle, the entire microneedle from the substrate to the needle swells quickly, and the dissolution rate of the needle in the skin increases. Therefore, the microneedle which has conventionally required 1 to 3 hours for dissolution is dissolved in 10 to 30 minutes.
The microneedle of the present invention is made of a substance dissolved in a living body such as hyaluronic acid or collagen, and the length of the microneedle is 30 to 1000 μm. The size of the substrate of the microneedle array is not particularly limited, but typically the substrate area is 0.5 to 40 cm 2 and the substrate thickness is 10 to 2000 μm. Also, the shape can be various shapes such as a circle, an ellipse, a ball shape, and a face mask.
マイクロニードルアレイの基板背面から大量の水分を供給することにより、マイクロニードルアレイを素早く膨潤させることが可能となり、マイクロニードルの皮膚内での溶解速度を大幅に加速することができた。そのためマイクロニードルの溶解時間を従来の１〜３時間から１０〜３０分に短縮でき、日常的に使用できるようになったほか、皮膚科診察室や美容室での使用が現実的となり、マイクロニードルアレイの使用性が向上した。By supplying a large amount of moisture from the back surface of the substrate of the microneedle array, the microneedle array can be swollen quickly, and the dissolution rate of the microneedle in the skin can be greatly accelerated. Therefore, the dissolution time of microneedles can be shortened from 1 to 3 hours to 10 to 30 minutes and can be used on a daily basis. In addition, microneedles can be used in dermatological examination rooms and beauty salons. Improved usability of the array.
次に、本発明の実施例を図面を参照して詳細に説明するが、本発明は実施例に限定されるものではない。また、本発明のマイクロニードルアレイは、従来法により製造した（特許文献３，４）。Next, examples of the present invention will be described in detail with reference to the drawings. However, the present invention is not limited to the examples. Moreover, the microneedle array of the present invention was manufactured by a conventional method (Patent Documents 3 and 4).
本発明のマイクロニードルアレイ（１１）は、図１に示すような楕円形である。図１の（ａ）は平面図であり、（ｂ）はＡ−Ａ’線での断面図である。その大きさは長辺が約３０ｍｍ、短辺が約２０ｍｍである。マイクロニードルアレイの背部に、アレイの大きさより各方向に５ｍｍ大きいポリエチレン製粘着テープ（１２）を貼付した。図１に示すように、このテープの中心部分は、周辺各２ｍｍを残し切り取られている。但し、図に書き込まれたニードルの数は多くないが、実際は従来同様１ｃｍ２あたり１４４個形成されている。Microneedle arrays of the present invention (11) is elliptical as shown in FIG. 1A is a plan view, and FIG. 1B is a cross-sectional view taken along the line AA ′. The size of the long side is about 30 mm and the short side is about 20 mm. A polyethylene adhesive tape (12) that was 5 mm larger in each direction than the size of the array was attached to the back of the microneedle array. As shown in FIG. 1 , the central portion of the tape is cut off leaving 2 mm for each periphery. However, although the number of needles written in the figure is not large, 144 needles are actually formed per 1 cm 2 as in the prior art.
このマイクロニードルアレイ（１１）を皮膚に貼付して刺入し、その上（背面）に美容液含有シート状マスク（エリクシールシュペリエル レチノバイタル アイマスク、株式会社資生堂製）（１３）を押しつけた状態を図２に示す。但し図では皮膚は記載を省略している。
２０分後取り外し、剥離後の基板を顕微鏡で観察したところマイクロニードルは１００％溶けており全く残存していなかったことを確認した。
なお、美容液含有シート状マスクの代わりに、布か目の粗い紙を楕円形あるいは勾玉型に切り抜いたシートに化粧水（ＳＫ−ＩＩフェイシャルトリートメント エッセンス、Ｐ＆Ｇジャパン）を染み込ませたものを用いても好ましい結果が得られた。The microneedle array (11) was applied to the skin and inserted, and a state-of-the-art sheet mask (Elixir Superier Retino Vital Eye Mask, manufactured by Shiseido Co., Ltd.) (13) was pressed on the back (back). As shown in FIG . However, the illustration of the skin is omitted in the figure.
After 20 minutes, the substrate was removed and the peeled substrate was observed with a microscope, and it was confirmed that the microneedle was 100% dissolved and did not remain at all.
In addition, instead of using a essence-containing mask, use a sheet of paper or coarse paper cut into an oval shape or a pendulum shape soaked with lotion (SK-II Facial Treatment Essence, P & G Japan). Also favorable results were obtained.
本発明によるマイクロニードル適用方法は、医療や美容の分野において広く利用されるものと期待される。The microneedle application method according to the present invention is expected to be widely used in the fields of medicine and beauty.
１１．．．．．．マイクロニードルアレイ
１２．．．．．．粘着テープ
１３．．．．．．美容液含有シート11. . . . . .
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012149875A JP5746101B2 (en) | 2012-06-18 | 2012-06-18 | Rapid dissolution method of microneedles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012149875A JP5746101B2 (en) | 2012-06-18 | 2012-06-18 | Rapid dissolution method of microneedles |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010088144A Division JP5408592B2 (en) | 2010-03-19 | 2010-03-19 | Rapid dissolution method of microneedles |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014044384A Division JP2014128711A (en) | 2014-02-19 | 2014-02-19 | Rapid dissolution method for microneedle |
| JP2015094604A Division JP2015134288A (en) | 2015-05-07 | 2015-05-07 | Rapid dissolution method for microneedle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013009960A true JP2013009960A (en) | 2013-01-17 |
| JP5746101B2 JP5746101B2 (en) | 2015-07-08 |
Family
ID=47684379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012149875A Active JP5746101B2 (en) | 2012-06-18 | 2012-06-18 | Rapid dissolution method of microneedles |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5746101B2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670467B2 (en) | 2005-04-11 | 2017-06-06 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
| US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| US10603477B2 (en) | 2014-03-28 | 2020-03-31 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
| CN111918691A (en) * | 2018-03-30 | 2020-11-10 | 实验室和人们 | Multifunctional microneedle |
| US11065428B2 (en) | 2017-02-17 | 2021-07-20 | Allergan, Inc. | Microneedle array with active ingredient |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7335061B2 (en) * | 2018-06-29 | 2023-08-29 | ロレアル | Beauty method using microneedle sheet |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004503341A (en) * | 2000-07-17 | 2004-02-05 | ベクトン ディキンソン アンド カンパニー | Dosing device for transdermally administering substances |
| JP2007535346A (en) * | 2004-03-24 | 2007-12-06 | コリウム インターナショナル， インコーポレイテッド | Transdermal delivery device |
| JP2009273872A (en) * | 2008-04-14 | 2009-11-26 | Kosumedei Seiyaku Kk | Microneedle array |
| JP2010029634A (en) * | 2008-07-01 | 2010-02-12 | Kosumedei Seiyaku Kk | Microneedle array and method for manufacturing the same |
| JP2010046548A (en) * | 2002-06-25 | 2010-03-04 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
-
2012
- 2012-06-18 JP JP2012149875A patent/JP5746101B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004503341A (en) * | 2000-07-17 | 2004-02-05 | ベクトン ディキンソン アンド カンパニー | Dosing device for transdermally administering substances |
| JP2010046548A (en) * | 2002-06-25 | 2010-03-04 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
| JP2007535346A (en) * | 2004-03-24 | 2007-12-06 | コリウム インターナショナル， インコーポレイテッド | Transdermal delivery device |
| JP2009273872A (en) * | 2008-04-14 | 2009-11-26 | Kosumedei Seiyaku Kk | Microneedle array |
| JP2010029634A (en) * | 2008-07-01 | 2010-02-12 | Kosumedei Seiyaku Kk | Microneedle array and method for manufacturing the same |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9885024B2 (en) | 1998-08-06 | 2018-02-06 | Duke University | PEG-urate oxidase conjugates and use thereof |
| US11781119B2 (en) | 2005-04-11 | 2023-10-10 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
| US9926537B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US9926538B2 (en) | 2005-04-11 | 2018-03-27 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US10160958B2 (en) | 2005-04-11 | 2018-12-25 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US10731139B2 (en) | 2005-04-11 | 2020-08-04 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US11345899B2 (en) | 2005-04-11 | 2022-05-31 | Horizon Therapeutics Usa, Inc. | Variant forms of urate oxidase and use thereof |
| US9670467B2 (en) | 2005-04-11 | 2017-06-06 | Horizon Pharma Rheumatology Llc | Variant forms of urate oxidase and use thereof |
| US10139399B2 (en) | 2009-06-25 | 2018-11-27 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| US11982670B2 (en) | 2009-06-25 | 2024-05-14 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US10823727B2 (en) | 2009-06-25 | 2020-11-03 | Horizon Pharma Rheumatology Llc | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US11639927B2 (en) | 2009-06-25 | 2023-05-02 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| US11598767B2 (en) | 2009-06-25 | 2023-03-07 | Horizon Therapeutics Usa, Inc. | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| US10987503B2 (en) | 2014-03-28 | 2021-04-27 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
| US10603477B2 (en) | 2014-03-28 | 2020-03-31 | Allergan, Inc. | Dissolvable microneedles for skin treatment |
| US11065428B2 (en) | 2017-02-17 | 2021-07-20 | Allergan, Inc. | Microneedle array with active ingredient |
| CN111918691B (en) * | 2018-03-30 | 2022-07-15 | 实验室和人们 | Multifunctional microneedle |
| JP7125998B2 (en) | 2018-03-30 | 2022-08-25 | ラブンピープル カンパニー リミテッド | Multi-type microneedle |
| JP2021517048A (en) * | 2018-03-30 | 2021-07-15 | ラブンピープル カンパニー リミテッドＬａｂｎｐｅｏｐｌｅ Ｃｏ．，Ｌｔｄ． | Multi-type microneedle |
| CN111918691A (en) * | 2018-03-30 | 2020-11-10 | 实验室和人们 | Multifunctional microneedle |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5746101B2 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5408592B2 (en) | Rapid dissolution method of microneedles | |
| JP5746101B2 (en) | Rapid dissolution method of microneedles | |
| JP6121674B2 (en) | Microneedle rapid dissolution method | |
| JP6402714B2 (en) | Microneedle unit | |
| US10646702B2 (en) | Microneedle, mould for producing same, and production method for same | |
| US20080200883A1 (en) | Micro-needle and micro-needle patch | |
| JP5495034B2 (en) | Multi-needle microneedle patch | |
| WO2011016230A1 (en) | Applicator device of pinholder type microneedle | |
| WO2017130793A1 (en) | Microneedle array, and microneedle sheet | |
| TW201210646A (en) | Device having array provided with fine protrusions | |
| TW200841866A (en) | Cosmetic or medical patch structure | |
| Zhang et al. | Use of drawing lithography-fabricated polyglycolic acid microneedles for transdermal delivery of itraconazole to a human basal cell carcinoma model regenerated on mice | |
| Arbache et al. | Microinfusion of drugs into the skin with tattoo equipment | |
| JP2012024240A (en) | Pasting aid of plaster for microneedle | |
| JP2015134288A (en) | Rapid dissolution method for microneedle | |
| Alshammari et al. | An update on microneedle in insulin delivery: quality attributes, clinical status and challenges for clinical translation | |
| JP2014128711A (en) | Rapid dissolution method for microneedle | |
| KR101460499B1 (en) | Method for manufacturing microneedle device | |
| CN210494885U (en) | Metal drug-storing micro-needle patch | |
| JP2014023697A (en) | Needle-like body package | |
| US20180200495A1 (en) | Administration device | |
| CN211863571U (en) | Microneedle | |
| JP5222512B2 (en) | Micro needle tip | |
| KR20100094700A (en) | The treatment and skin care system connected with micro-needle stamp | |
| JP2015136527A (en) | Microneedle unit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141002 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150406 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5746101 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |